Table 1.
Muramyl peptides registered and investigated as medicinal products.
| Trade name INN Company | Chemical Names | Applying | Country/Date of registration |
|---|---|---|---|
|
Nopia®/Romurtide, Muroctasin, Daiichi Pharmaceutic |
N-Acetylmuramyl-Ala-D-isoglutaminyl-Nϵ-stearoyl-Lys,DJ-7041, MDP-Lys(L18) | Oncology, Neutropenia | Japan/1991 |
|
B30-MDP
Daiichi Pharmaceutic |
6-O-(2-tetradecylhexadecanoyl)-N-acetylmuramoyl-L-alanyl-D-isoglutamine) | Infectious diseases (adjuvant in influenza vaccine) | Japan/1992 |
|
Licopid®
AO Peptek, |
N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine, GMDP | Chronic recurrent respiratory tract infections, inflammatory diseases of skin and soft tissues, psoriasis, herpetic infections | Russia/1995; Belarus, Kazakhstan/2001; Azerbaijan, Armenia, Moldova/2007; Uzbekistan, Kyrgyzstan, Mongolia, Georgia/2015 |
|
Threonyl Muramyl Dipeptide
BOC Sciences |
Threonyl-N-Acetylmuramyl-Ala-D-isoglutamine Threonyl-MDP |
HIV infection (adjuvant in AIDS vaccine) | USA, phase I/1996 The release of the medicinal product is suspended |
|
ImmTher®
Immunotherapeutics Inc. |
N-acetylglucosamin-N- acetylmuramyl-L-alanyl-D- isoglutamine -L- alanyl- glyceryl dipalmitate, disaccharide tripeptide glycerol dipalmitoyl | Oncology | USA/2000 |
|
Liasten® (Blasten)
Technologist, |
glucosaminylmuramyl pentapeptide GMPP |
Infectious diseases, pulmonology, oncology, surgery | Ukraine/2000 |
|
Murabutide
ISTAK Biotechnology, |
N-acetylmuramyl-L-alanyl-D-isoglutamine-n-butyl ether | N-acetylmuramyl-L-alanyl-D-isoglutamine-n-butyl ether Infectious diseases, HIV infection |
France/2002 |
|
Mepact®, Junovan, Mifamurtide Takeda Pharmaceutical |
muramyltripeptide phosphatidyleanolamine incorporated into liposomes Liposomal Muramyltripeptide Phosphatidylethanolamine L-MTP-PE, MLV 19835A, MTP-PE |
Oncology (osteosarcoma), adjuvant in the vaccine against AIDS and hepatitis B |
27 countries of the European Union/2009 Mexico/2010 |
|
norMDP, Almurtide®
American Custom Chemicals Corp |
N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine,Cgp-11637, Nor-MDP,UNII-1DCO35D4OR | Oncology (adjuvant in vaccine) |
USA/1st phase 2011-2017 |
|
Polimuramil®
“Combotech” for LLC “CORUS PHARM” |
A complex of three components: 1) N-acetyl-D-glucosaminyl-N-acetyl-D-muramoyl-L-alanyl-D-isoglutaminyl-meso-diaminopimeli- new acid (HMtri); 2) N-acetyl-D-glucosaminyl-N-acetyl-D-muramoyl-L-alanyl-D-isoglutaminyl-meso-diaminopimeloyl-D-alanine (HMtetra); 3) dimer (HMtetra and diHMtetra) |
Secondary immunodeficiency states, acute and chronic pyoderma complicated by secondary infection, dermatoses, treatment and prevention of surgical infections | Russia/2013 |